Evidence map›Paper›PMID 34831006›Full record

ReviewCancers2021

An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features.

Ahmed Ebada Salem, Yehia H Zaki, Gamal El-Hussieny, Khaled I ElNoueam, Akram M Shaaban, Bhasker Rao Koppula, Mark Bustoros, Mohamed Salama, Khaled M Elsayes, Kathryn Morton and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Cell characterization of extranodal lymphoproliferative disorders.Journal of oral and maxillofacial pathology : JOMFP
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Ahmed Ebada SalemDepartment of Radiology and Imaging Sciences, Utah University School of Medicine, Salt Lake City, UT 84123, USA.
Yehia H ZakiDepartment of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University, Alexandria 21566, Egypt.
Gamal El-HussienyDepartment of Medical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Alexandria 21566, Egypt.
Khaled I ElNoueamDepartment of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University, Alexandria 21566, Egypt.
Akram M ShaabanDepartment of Radiology and Imaging Sciences, Utah University School of Medicine, Salt Lake City, UT 84123, USA.
Bhasker Rao KoppulaDepartment of Radiology and Imaging Sciences, Utah University School of Medicine, Salt Lake City, UT 84123, USA.
Mark BustorosDivision of Hematology and Medical Oncology, Weil Cornell Medicine, Cornell University, New York, NY 10021, USA.
Mohamed SalamaDepartment of Pathology, Mayo Clinic, Rochester, MN 55901, USA.
Khaled M ElsayesDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kathryn MortonDepartment of Radiology and Imaging Sciences, Utah University School of Medicine, Salt Lake City, UT 84123, USA.
Matthew F CovingtonDepartment of Radiology and Imaging Sciences, Utah University School of Medicine, Salt Lake City, UT 84123, USA.
University of Utah · USAlexandria University · EGCornell University · USMayo Clinic · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoproliferative disorders (LPD) are conditions characterized by the uncontrolled proliferation of B or T-cell lines. They encompass a wide spectrum of abnormalities, which may be broadly classified as reactive processes or malignant diseases, such as lymphoma, based on their cellular clonality and clinical behavior. While some of these disorders are rare, they may be encountered sporadically in clinical practice, causing diagnostic dilemmas owing to overlap in their clinical and imaging features with more common disorders. The updated 4th edition WHO classification of lymphoid neoplasms was released in 2016 to incorporate the rapid clinical, pathological, molecular biology and cytogenetic advances of some of these disorders. Despite these updates, very little information is presented in the literature from the radiology perspective. The aim of this article is to familiarize radiologists and other physicians with certain rare variants of B-cell lymphoproliferative disorders with a focus on imaging features of these disorders, as well as to provide an overview of some important updates contained within the new WHO classification of lymphoid neoplasms.

Indexed as

18F-FDG PET/CTlymphoproliferative disordersrare B-cell lymphomasupdatesWHO classification of hematologic malignancies

Identifiers

PMID34831006
PMCPMC8616256
OpenAlexW3215795610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.